Medical Science Liaison Reports

I am pleased to offer the following third-party reports selected on the basis of their relevance to the interests of pharmaceutical marketing professionals. You can order and pay for reprints by credit card online. John Mack, Publisher & Editor editor@news.pharma-mkting.com

Report List

Aspects of Medical Science Liaison Compliance and Activity-Auditing Regulatory scrutiny has focused on the direct- and indirect drivers on MSLs' activities. Therefore, companies should realize that the symbol (what function the MSL program reports to, what advanced degrees MSLs hold) does not matter as much as the substance (what MSLs are actually expected to do, who applies the greatest pressures on MSL objectives) when it comes to evaluating activity drivers. It now looks like the golden age of regulating industry's conduct is upon Pharma.. Order this article and learn more ... Expanded Summary Available. Order and pay for this reprint now using your credit card... ONLY $29.95 Download PDF file immediately after paying: Medical Science Liaisons: Biotech's Special Forces Biotechnology companies with a product commercialization strategy are deploying field-based medical science liaisons (MSLs) to increase awareness of a therapeutic market, support clinical trials, and educate the healthcare community on appropriate product utilization. Attracting experienced MSLs to smaller or younger companies remains a significant challenge for MSL directors. This article provides helpful suggestions that biotech and other science-based companies can use to build their MSL force. Order this article and learn more ... Expanded Summary Available. Order and pay for this reprint now using your credit card... ONLY $24.95 Download PDF file immediately after paying: Medical Science Liaison Roles: Enigma and Dilemma After many hundreds of millions of penalty dollars from questionable sales and marketing practices, are pharmaceutical companies finally doing the "right" thing, at least where MSL roles are concerned? Are MSL directors trying? And are they getting more support from upper management? Order this article and learn more ... Expanded Summary Available. Order and pay for this reprint now using your credit card... ONLY $29.95 Download PDF file immediately after paying: MSL Training Design with ROI in Mind If we define Medical Science Liaison (MSL) training as enabling an MSL to adopt a desired behavior or fulfill a desired performance expectation, we can readily see how most of what we call "training" is not really training at all. Most MSL training involves information sessions where we try to dump as much information on the MSL as we can in a given time period. The agenda can look impressive and the slide decks even more so, but when the MSL leaves the training, what behaviors and performance are shown as a result of the two or three days you and the MSL have just invested? In other words, what kind of ROI can you expect from MSL training? Expanded Summary Available. Order and pay for this reprint now using your credit card... ONLY $29.95 Download PDF file immediately after paying: Off-Label Information Dissemination, Safe Harbor, and MSLs This article discusses the often misinterpreted "safe harbor" and whether MSLs enjoy such protection when disseminating off-label information. Where, if anywhere, does the law ascribe "safe harbor" surrounding verbal and written dissemination of off-label use for a drug? Ironically, the term "safe harbor" is not found in FDAMA document. If a pharmaceutical employee works within the boundaries specified by what is collectively identified as "safe harbor," the company is safe. If the employee's actions fall outside the box, it is fair game. This does not mean it is illegal per se. Order this article and learn more ... Expanded Summary Available. Order and pay for this reprint now using your credit card... ONLY $24.95 Download PDF file immediately after paying: